SG/CALL/BRISTOL-MYERS SQUIBB/90/0.1/21.06.24 | Delayed Deutsche Boerse AG 08:25:44 22/05/2024 pm IST | ||
| 0.001 EUR | 0.00% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 0.001 | 0.00% |
| 21/24/21 | 0.001 | 0.00% |
| 20/24/20 | 0.001 | 0.00% |
| 17/24/17 | 0.001 | 0.00% |
| 16/24/16 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 08:25 pm IST
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ4FE9 |
| ISIN | DE000SQ4FE99 |
| Date issued | 16/11/2022 |
| Strike | 90 $ |
| Maturity | 21/06/2024 (30 Days) |
| Parity | 10 : 1 |
| Emission price | 0.55 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.67 € |
|---|---|
| Lowest since issue | 0.001 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 0.4708 |
| Difference Strike | 47.42 $ |
| Difference Strike % | +52.69% |
| Intrinsic value | 0.000000 |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.27
USD
Average target price
53.19
USD
Spread / Average Target
+25.84%
- Stock Market
- Warrants
- Warrant